$826 Million is the total value of Broadfin Capital, LLC's 55 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 111.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HRTX | Buy | HERON THERAPEUTICS INC | $74,211,000 | +45.3% | 4,947,403 | +26.9% | 8.99% | +58.5% |
| XBI | New | SPDR SERIES TRUSTput | $69,340,000 | – | 1,000,000 | +100.0% | 8.40% | – |
| AVDL | New | AVADEL PHARMACEUTICALS PLCsponsored adr | $42,538,000 | – | 4,394,464 | +100.0% | 5.15% | – |
| RXDX | Buy | IGNYTA INC | $22,681,000 | +89.6% | 2,637,346 | +16.9% | 2.75% | +106.9% |
| ENDP | New | ENDO INTL PLCcall | $22,320,000 | – | 2,000,000 | +100.0% | 2.70% | – |
| ENDP | Buy | ENDO INTL PLC | $21,023,000 | -18.2% | 1,883,738 | +20.7% | 2.55% | -10.8% |
| HZNP | Buy | HORIZON PHARMA PLCcall | $14,780,000 | +14.2% | 1,000,000 | +25.0% | 1.79% | +24.6% |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $14,163,000 | +103.9% | 2,981,706 | +3.0% | 1.72% | +122.4% |
| ELGX | Buy | ENDOLOGIX INC | $12,084,000 | +40.8% | 1,669,020 | +11.3% | 1.46% | +53.6% |
| CORI | Buy | CORIUM INTL INC | $11,650,000 | +49.5% | 2,787,121 | +45.2% | 1.41% | +63.1% |
| ARLZ | Buy | ARALEZ PHARMACEUTICALS INC | $11,110,000 | -47.4% | 5,191,590 | +8.3% | 1.35% | -42.6% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $10,872,000 | +177.1% | 2,090,801 | +153.1% | 1.32% | +202.1% |
| DXCM | New | DEXCOM INC | $4,177,000 | – | 49,300 | +100.0% | 0.51% | – |
| JUNO | New | JUNO THERAPEUTICS INC | $3,899,000 | – | 175,700 | +100.0% | 0.47% | – |
| OMED | New | ONCOMED PHARMACEUTICALS INCcall | $2,763,000 | – | 300,000 | +100.0% | 0.34% | – |
| PGNX | New | PROGENICS PHARMACEUTICALS INcall | $2,360,000 | – | 250,000 | +100.0% | 0.29% | – |
| AVGR | New | AVINGER INC | $950,000 | – | 500,000 | +100.0% | 0.12% | – |
| GNMX | New | AEVI GENOMIC MEDICINE INCcall | $930,000 | – | 500,000 | +100.0% | 0.11% | – |
| ATEC | New | ALPHATEC HOLDINGS INC | $527,000 | – | 226,006 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.